Kingray Capital
VC Fund
Kingray Capital is an Investment firm.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Kingray Capital invests in
Stages Kingray Capital invests in
Countries Kingray Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Huang Pu
|
|||
4 more contacts available
Investment Focus
Industry
- Biotechnology 3 (17%)
- Electronics 2 (11%)
- Therapeutics 2 (11%)
- Semiconductor 2 (11%)
- Pharmaceutical 2 (11%)
Stage
- Series A 2 (11%)
- Seed 1 (6%)
- Series B 1 (6%)
- Series C 1 (6%)
- Series D 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Huang Pu
Managing Partner
|
Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Immunocan
|
Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs. | $36.8M / Series A / May 13, 2026 | |
Tauren
|
Tauren is a domestic and hybrid design enterprise of analog and analog-digital chips. At present, the company has won the recognition of the top first-line customers and the strong support of the first-line investment institutions; in the future, it will continue to cultivate the analog and analog-digital hybrid design track, and provide highlycompetitive standardized products for the market landing demand. Provide customers with stable and first-class quality semiconductor products. | Series E / Jan 21, 2026 | |
Panmeng Semiconductor
|
Panmeng Semiconductor produces semiconductor-grade silicon wafers and provides grinding, etching, and polishing services, which are critical for advancing the domestic semiconductor and electronics industries. | $14.2M / Series A / Dec 18, 2025 | |
Alebund Pharmaceuticals
|
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $75.1M / Series C / Jan 07, 2025 | |
|
Immunocan
|
Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs. | Venture - Series Unknown / Jan 01, 2025 | |
IMPACT Therapeutics
|
IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more thanfour decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology. | $55.3M / Series D / Apr 19, 2024 | |
TopOlefin Technology
|
TopOlefin Technology engages in the research, development and production of advanced, green, intelligent and high-end polymer new materials. | $141.7M / Series B / Jul 21, 2023 | |
Zhitong Precision
|
Zhitong Precision is a producer of industrial robots. They provide products that include machine tools, wind power, AGV cars, ships, construction machinery, and high-speed rail. They offer components and industrial automation production line solutions. | Venture - Series Unknown / Mar 13, 2023 | |
|
Immunocan
|
Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs. | Venture - Series Unknown / Jan 01, 2023 | |
Trinomab
|
Trinomab is a Healthcare company. | $104.7M / Venture - Series Unknown / Nov 29, 2022 | |
| See all 18 investments → | |||
Co-Investors
ShenZhen GTJA Investment Group
3 deals together
Taiyu Investment
3 deals together
EFung Capital
2 deals together
Beijing E-town International Investment & Development
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Kingray Capital invest in?
Kingray Capital invests primarily in Biotechnology, Electronics and Therapeutics startups, most often at Series A and Seed stage. Most of the 18 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Kingray Capital?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Kingray Capital?
The team at Kingray Capital includes Huang Pu (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
